A clinical drug development programme to evaluate and compare the safety and efficacy of new regimens of Lifecare's Liposomal Amphotericin b (FUNGISOMETM) against currently accepted therapies for the treatment of Kala Azar; A Phase III, Open Label Randomized Trial of Three Single Dose Treatment regimens of FUNGISOMETM ALONE OR IN Combination with Miltefosine compared with single Dose Treatment regimen of AmBisome for visceral Leishmaniasis in India | India Science, Technology & Innovation - ISTI Portal

×

Acces sibility Controls

A clinical drug development programme to evaluate and compare the safety and efficacy of new regimens of Lifecare's Liposomal Amphotericin b (FUNGISOMETM) against currently accepted therapies for the treatment of Kala Azar; A Phase III, Open Label Randomized Trial of Three Single Dose Treatment regimens of FUNGISOMETM ALONE OR IN Combination with Miltefosine compared with single Dose Treatment regimen of AmBisome for visceral Leishmaniasis in India

Implementing Organization

Lifecare Innovations Private Limited, Gurgaon, Haryana

Principal Investigator

Dr. J N Verma

Gurgaon, Haryana (122018)

Lifecare Innovations Private Limited

Related Research

Quick Information

Area of Research

Pharmaceutical Sciences

Focus Area

Pharmacology and Infectious Diseases

Start Year

2024

End Year

2031

Sanction Amount

₹ 6.86 Cr

Status

Ongoing

Output

No. of Research Paper

00

Technologies (If Any)

00

No. of PhD Produced

N/A

Startup (If Any)

00

No. of Patents

Filed :00

Grant :00